JMT-101 is an anti-EGFR mAb which has shown favorable a toxicity profile in patients with colorectal cancer [81] and is being assessed in combination with afatinib or osimertinib in a phase Ib trial in patients with EGFR exon 20 insertion mutations (NCT04448379). The gene discussed is EGFR; the disease is colorectal cancer.